KMCRIC

PARP and novel DNA Damage Response (DDR) inhibitors are showing great potential in broader tumor indications as they advance through the clinic. This industry-focused summit will equip you with the tools to optimize PARP inhibitors for expanded indications; create best-in-class therapeutics; over-ride resistance and identify novel DDR and synthetic lethal pathways to exploit cancer survival mechanisms.